Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Atenolol Clear all
Terminated Not applicable Interventional Results available

Multimodal Treatment Strategy for Cancer Cachexia

NCT00625742
View directory record Official record
Conditions
Advanced Cancer, Cachexia
Interventions
Graded Resistance Training, Aerobic Exercise, Melatonin, Juven, Atenolol, Ibuprofen
Behavioral · Drug · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Not applicable Interventional Results available

Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation

NCT01719367
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Atenolol
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2019 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

NCT00158093
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Atenolol, Moxifloxacin
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2005 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques

NCT01230892
View directory record Official record
Conditions
Atherosclerosis, Endothelial Function
Interventions
Nebivolol, Atenolol
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 79 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 4 Interventional

INVEST: INternational VErapamil SR Trandolapril STudy

NCT00133692
View directory record Official record
Conditions
Hypertension, Coronary Artery Disease
Interventions
Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ), Atenolol/HCTZ/Trandolapril
Drug
Lead sponsor
University of Florida
Other
Eligibility
50 Years and older
Enrollment
22,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Sep 2, 2026, 10:02 AM EDT
Not listed Early Phase 1 Interventional

Use of Impedance Cardiography to Decrease the Risk of Pre-eclampsia in Obese Patients

NCT03105661
View directory record Official record
Conditions
Obesity, Morbid, Preeclampsia
Interventions
Labetalol Hydrochloride 200 mg, NIFEdipine 60 mg, Atenolol 25 mg
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Impact of Beta-blockers on Physical Function in HFpEF

NCT04767061
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Disease
Interventions
Beta blockers
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 2, 2026, 10:02 AM EDT
Withdrawn Phase 4 Interventional

EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network

NCT01748123
View directory record Official record
Conditions
Hypertension
Interventions
Chlorthalidone, Hydrochlorothiazide
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 4 Interventional

Elder Surgery - Functional Recovery Following Beta Blockade

NCT00507663
View directory record Official record
Conditions
Post Operative Cognitive Dysfunction
Interventions
Atenolol
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
65 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Sep 2, 2026, 10:02 AM EDT
Withdrawn Phase 3 Interventional

Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome

NCT01361087
View directory record Official record
Conditions
Marfan Syndrome
Interventions
Blood draw
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Months to 24 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 2, 2026, 10:02 AM EDT
Withdrawn Not applicable Interventional

Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study

NCT01009944
View directory record Official record
Conditions
Hypertension
Interventions
Lisinopril, Atenolol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Sep 2, 2026, 10:02 AM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Atenolol 100mg Tablets Under Fasting Conditions

NCT00775580
View directory record Official record
Conditions
Healthy
Interventions
Atenolol 100mg Tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Chapell Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2008 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomic Evaluation of Antihypertensive Responses

NCT00246519
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide, Atenolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
17 Years to 65 Years
Enrollment
1,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
Gainesville, Florida • Atlanta, Georgia • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 2 Interventional

A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension

NCT00200421
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol and Atenolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2005 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure

NCT00669279
View directory record Official record
Conditions
Hypertension
Interventions
Carvedilol CR, Atenolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 4 Interventional

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

NCT00185094
View directory record Official record
Conditions
Hypertension, Insulin Resistance, Metabolic Syndrome
Interventions
Olmesartan medoxomil, Losartan potassium, Atenolol
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2005 · Synced Sep 2, 2026, 10:02 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones

NCT01795235
View directory record Official record
Conditions
Healthy
Interventions
Saline, Glucagon, Placebo, Atenolol
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 2, 2026, 10:02 AM EDT
Withdrawn Phase 2 Interventional

4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine

NCT03578354
View directory record Official record
Conditions
Vestibular Migraine, Migraine Disorders, Vestibular Diseases
Interventions
4-aminopyridine, Atenolol, Placebo
Drug · Other
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Not applicable Interventional

Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers

NCT00607347
View directory record Official record
Conditions
Hypertension
Interventions
Glucose
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

Reducing Total Cardiovascular Risk in an Urban Community

NCT00241904
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Coronary Disease, Diabetes Mellitus, Atherosclerosis, Cerebral Arteriosclerosis, Hypertension
Interventions
Lifestyle Changes, Antiplatelet Agents, Beta Blocker, ACE Inhibitors
Behavioral · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 80 Years
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Sep 2, 2026, 10:02 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy

NCT04755764
View directory record Official record
Conditions
Systolic Hypertension, Pregnancy Related, Diastolic Hypertension, Cardiac Output, Low, Cardiac Output, High
Interventions
Labetalol, Atenolol, Nifedipine
Drug
Lead sponsor
Marshall University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects

NCT02262533
View directory record Official record
Conditions
N/A - Healthy Subjects
Interventions
Apixaban, Atenolol
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 9, 2015 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Not applicable Interventional

Cognitive/Cerebrovascular Consequences of HTN Treatment

NCT00151138
View directory record Official record
Conditions
Hypertension
Interventions
Atenolol (drug), Lisinopril (drug)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
35 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2007 · Synced Sep 2, 2026, 10:02 AM EDT